Junshi Biosciences is an innovation-driven biopharmaceutical company with a focus on discovery and innovative drugs. Dr Li Ning, CEO, discusses being the first Chinese company to successfully launch a domestically-developed PD-1 cancer drug (toripalimab) in China, their commercialization and pricing strategies and the exciting new products and milestones that we can expect from Junshi in the upcoming years.
The China market is highly diversified and extremely competitive, therefore ethics and safety to meet ... unmet medical needs is key
